Skip to main content

Table 1 Baseline demographics, clinical characteristics, and treatments of PBS patients

From: Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study

Characteristic

PBS patients n = 211

Age, years, mean (SD)

44.6 (12.5)

Duration of CM, mean (SD) years

14.5 (12.3)a

Women, n (%)

187 (88.6)

Baseline headache days/month, mean (SD)

25.2 (5.3)

Baseline migraine days/month, mean (SD)

15.3 (7.9)b

Baseline HIT-6 score, mean (SD)

68.2 (4.8)c

Patients with HIT-6 score indicating severe impact (≥60)

98.0%d

Previously used preventive headache medication

 Amitriptyline

152 (72.0)

 Topiramate

151 (71.6)

 Propranolol

143 (67.8)

 Pizotifen

122 (57.8)

 Sodium valproate

63 (29.9)

 Verapamil

43 (20.4)

 Candesartan

25 (11.8)

 Cyproheptadine

19 (9.0)

 Methysergide

14 (6.6)

 Other: Pregabalin

12 (5.7)

Continued use of oral preventive headache medication

66.4%

Acute medication overuse at baselinee

61.1%

Concomitant use of simple analgesics

74.4%

Concomitant use of triptans

64.5%

Concomitant use of prescribed opioids

23.2%

  1. CM, chronic migraine; HIT-6, 6-item Headache Impact Test; PBS, Pharmaceutical Benefits Scheme
  2. an = 124
  3. bn = 197
  4. cn = 100
  5. dn = 100
  6. eAs suggested by patient’s records noting a management plan for medication overuse